Transcriptomics

Dataset Information

0

The SUMO Pathway as a Therapeutic Option in Pancreatic Cancer


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with overall five-year survival of 8%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC, however subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumor biology. It is clear that hyperactivation of MYC generates dependencies, which can be exploited therapeutically. To find MYC-associated dependency we analyzed human PDAC expression dataset. We observed that MYC is connected to the sumoylation machinery in PDAC. Components of the SUMO pathway mark a PDAC subtype with worse prognosis and we provide evidence that PDACs with a MYChigh/SUMOhigh phenotype respond to a novel SUMO inhibitor, offering the opportunity to develop novel stratified PDAC therapies

ORGANISM(S): Homo sapiens

PROVIDER: GSE119423 | GEO | 2019/01/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-01-06 | PXD011347 | Pride
2024-02-18 | GSE244326 | GEO
2024-02-18 | GSE244287 | GEO
2024-04-06 | PXD046026 | Pride
2023-03-17 | PXD038620 | Pride
| PRJNA817622 | ENA
2023-03-17 | PXD038617 | Pride
| PRJNA489233 | ENA
2012-12-16 | E-GEOD-42322 | biostudies-arrayexpress
2018-10-24 | GSE115842 | GEO